anorectal cancer
Conditions
Interventions
Product Name: F-18 FLT
Product Code: -
Pharmaceutical Form: Solution for injection
Sponsors
Prim. Univ.Prof. Dr. Christian Pirich Department of Nuclear Medicine and Endocrinology, PMU Salzburg
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Included in this study will be between 18 and 80 years old male and female patients with proven rectal tumour (by biopsy and histology). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Excluded from this study are patients that are not able to lie motionless without pain for one hour, pregnant women and breast-feading women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The comparison of F-18 FLT and F-18 FDG tumour uptake before and after neoadjuvant radiochemotherapy (related to clinical, radiological and PET-CT criteria of response) and the evaluation of the tumour response to therapy. ;Secondary Objective: The relation and comparison of the F-18 FLT and F-18 FDG uptake pattern of rectal tumours to the molecular tumour pattern and the determination of differences of F-18 FLT and F-18 FDG uptake (degree of tumour proliferation, glycolysis and histological signs of concomitant inflammation).;Primary end point(s): ? | — |
Countries
Austria
Outcome results
None listed